Search results
Results from the WOW.Com Content Network
Men with breast cancer have an absolute risk of presenting with a second cancer in their other breast of 1.75, i.e. they have a 75% increase of developing a contralateral breast cancer over their lifetimes compared to men who develop a breast cancer without having had a prior breast cancer. [5]
Gender-affirming hormone therapy (GAHT), also called hormone replacement therapy (HRT) or transgender hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity.
A single retrospective study in the medical literature of 293 trans men treated with testosterone (range of 2 months to 41 years) by the Amsterdam Gender Dysphoria Clinic from 1975 to 1994 showed no increase in cardiovascular mortality or morbidity when compared with the general female Dutch population. (As with all scientific studies, this ...
Breen’s suit claims Olson-Kennedy’s clinic put her on puberty blockers when she was just 12, started her on hormone therapy at 13 and performed a double mastectomy on her at 14.
One page that is dedicated to celebrating photography from history is Old-Time Photos on Facebook. This account shares digitized versions of photos from the late 1800s all the way up to the 1980s.
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...